KLRC1 and cancer: From a therapeutic perspective, humanized monoclonal antibodies targeting NKG2A (Monalizumab) are readily available and currently in clinical trials for cancer, hence representing a promising strategy for future clinical studies in HLA-E positive ovarian tumors.